$IBRX INSIGHTS →IBRX stock surged +40% after EU granted conditional approval for ANKTIVA in BCG-unresponsive bladder cancer.
Read the full research in the app
A subscription is required to access the full thread.
Open in the app →$IBRX INSIGHTS →$IBRX INSIGHTS →